Microsomal prostaglandin e synthase 1 deletion retards renal disease progression but exacerbates anemia in mice with renal mass reduction

Hypertension

Volumn 59, Issue 1, 2012, Pages 122-128

  Jia, Zhanjun ^a   Wang, Haiping ^a   Yang, Tianxin ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

chronic renal failure; cyclooxygenase 2; microsomal prostaglandin E synthase 1; prostaglandin E 2; proteinuria

Indexed keywords

ALBUMIN; CREATININE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; NEPHRIN; NITROGEN; PHOSPHORUS; PROSTAGLANDIN E SYNTHASE 1; TUMOR NECROSIS FACTOR ALPHA; UREA;

ALBUMINURIA; ANEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DISEASE EXACERBATION; GLOMERULOSCLEROSIS; GLOMERULUS INJURY; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY TUMOR; MOUSE; NEPHRECTOMY; NONHUMAN; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UREA NITROGEN BLOOD LEVEL;

ANEMIA; ANIMALS; BLOOD PRESSURE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; GENE DELETION; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY CONCENTRATING ABILITY; KIDNEY GLOMERULUS; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, KNOCKOUT; MICROSOMES; NEPHRECTOMY; RENAL INSUFFICIENCY, CHRONIC;

EID: 83655184681     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.178897     Document Type: Article

References (36)

1. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15:1-12. (Pubitemid 38020692)
2. Murakami M, Kudo I. Prostaglandin E synthase: a novel drug target for inflammation and cancer. Curr Pharm Des. 2006;12:943-954.
3. Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: a novel therapeutic target. Pharmacol Rev. 2007; 59:207-224. (Pubitemid 47481434)
4. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, Umland JP, Pandher K, Lapointe JM, Saha S, Roach ML, Carter D, Thomas NA, Durtschi BA, McNeish JD, Hambor JE, Jakobsson PJ, Carty TJ, Perez JR, Audoly LP. Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. Proc Natl Acad Sci USA. 2003;100:9044-9049. (Pubitemid 36899220)
5. Jia Z, Zhang A, Zhang H, Dong Z, Yang T. Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res. 2006;99:1243-1251. (Pubitemid 44808661)
6. Jia Z, Aoyagi T, Kohan DE, Yang T. mPGES-1 deletion impairs aldosterone escape and enhances sodium appetite. Am J Physiol Renal Physiol 299:F155-F166.
7. Jia Z, Aoyagi T, Yang T. mPGES-1 protects against DOCA-salt hypertension via inhibition of oxidative stress or stimulation of NO/cGMP. Hypertension. 55:539-546.
8. Jia Z, Wang H, Yang T. Mice lacking mPGES-1 are resistant to lithiuminduced polyuria. Am J Physiol Renal Physiol. 2009;297:F1689-F1696.
9. Francois H, Facemire C, Kumar A, Audoly L, Koller B, Coffman T. Role of microsomal prostaglandin E synthase 1 in the kidney. J Am Soc Nephrol. 2007;18:1466-1475. (Pubitemid 46717513)
10. Stitt-Cavanagh EM, Faour WH, Takami K, Carter A, Vanderhyden B, Guan Y, Schneider A, Breyer MD, Kennedy CR. A maladaptive role for EP4 receptors in podocytes. J Am Soc Nephrol 21:1678-1690.
11. Wang JL, Cheng HF, Zhang MZ, McKanna JA, Harris RC. Selective increase of cyclooxygenase-2 expression in a model of renal ablation. Am J Physiol. 1998;275:F613-F622.
12. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int. 2000;57:2334-2342. (Pubitemid 30340732)
13. Cheng H, Wang S, Jo YI, Hao CM, Zhang M, Fan X, Kennedy C, Breyer MD, Moeckel GW, Harris RC. Overexpression of cyclooxygenase-2 predisposes to podocyte injury. J Am Soc Nephrol. 2007;18: 551-559. (Pubitemid 46193320)
14. Cheng H, Fan X, Guan Y, Moeckel GW, Zent R, Harris RC. Distinct roles for basal and induced COX-2 in podocyte injury. J Am Soc Nephrol. 2009;20:1953-1962.
15. Bek M, Nusing R, Kowark P, Henger A, Mundel P, Pavenstadt H. Characterization of prostanoid receptors in podocytes. J Am Soc Nephrol. 1999;10:2084-2093. (Pubitemid 29453485)
16. Purkerson ML, Joist JH, Yates J, Valdes A, Morrison A, Klahr S. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA. 1985;82:193-197. (Pubitemid 15168241)
17. Zoja C, Perico N, Corna D, Benigni A, Gabanelli M, Morigi M, Bertani T, Remuzzi G. Thromboxane synthesis inhibition increases renal prostacyclin and prevents renal disease progression in rats with remnant kidney. J Am Soc Nephrol. 1990;1:799-807.
18. Zoja C, Perico N, Bergamelli A, Pasini M, Morigi M, Dadan J, Belloni A, Bertani T, Remuzzi G. Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney Int. 1990;37:934-942. (Pubitemid 20089226)
19. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension. 1999;34:848-853. (Pubitemid 29501311)
20. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol. 2006;17:2974-2984. (Pubitemid 44707757)
21. Ghosh SS, Massey HD, Krieg R, Fazelbhoy ZA, Ghosh S, Sica DA, Fakhry I, Gehr TW. Curcumin ameliorates renal failure in 5/6 nephrec-tomized rats: role of inflammation. Am J Physiol Renal Physiol. 2009; 296:F1146-F1157.
22. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimburger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF-β: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233. (Pubitemid 40463099)
23. Taal MW, Zandi-Nejad K, Weening B, Shahsafaei A, Kato S, Lee KW, Ziai F, Jiang T, Brenner BM, MacKenzie HS. Proinflammatory gene expression and macrophage recruitment in the rat remnant kidney. Kidney Int. 2000;58:1664-1676.
24. Hostetter TH, Olson JL, Rennke HG, Venkatachalam MA, Brenner BM. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol. 1981;241:F85-F93. (Pubitemid 11033923)
25. Pelayo JC, Shanley PF. Glomerular and tubular adaptive responses to acute nephron loss in the rat: effect of prostaglandin synthesis inhibition. J Clin Invest. 1990;85:1761-1769. (Pubitemid 20192947)
26. Fisher JW, Hagiwara M. Effects of prostaglandins on erythropoiesis. Blood Cells. 1984;10:241-260. (Pubitemid 16239819)
27. Ortega JA, Dukes PP, Ma A, Shore NA, Malekzadeh MH. A clinical trial of prostaglandin E2 to increase erythropoiesis in anemia of end stage renal disease: a preliminary report. Prostaglandins Leukot Med. 1984;14: 411-416. (Pubitemid 14111900)
28. Arce JM, Naughton BA, Kolks GA, Liu P, Gordon AS, Piliero SJ. The effect of prostaglandins A2, E1, E2,15 methyl E2, 16, 16 dimethyl E2 and F2βon erythropoiesis. Prostaglandins. 1981;21:367-377.
29. Fisher JW, Radtke HW, Jubiz W, Nelson PK, Burdowski A. Prostaglandins activation of erythropoietin production and erythroid progenitor cells. Exp Hematol. 1980;8(suppl 8):65-89. (Pubitemid 12220669)
30. Lorenz M, Slaughter HS, Wescott DM, Carter SI, Schnyder B, Dinchuk JE, Car BD. Cyclooxygenase-2 is essential for normal recovery from 5-fluorouracil-induced myelotoxicity in mice. Exp Hematol. 1999;27: 1494-1502. (Pubitemid 29458423)
31. Zhang F, Laneuville P, Gagnon RF, Morin B, Brox AG. Effect of chronic renal failure on the expression of erythropoietin message in a murine model. Exp Hematol. 1996;24:1469-1474. (Pubitemid 26418552)
32. Sanada S, Toyama H, Ejima Y, Matsubara M. Potential for erythropoietin synthesis in kidney of uraemic rat alters depending on severity of renal failure. Nephrology (Carlton). 2009;14:735-742.
33. Fukushima Y, Fukuda M, Yoshida K, Yamaguchi A, Nakamoto Y, Miura AB, Harada T, Tsuchida S. Serum erythropoietin levels and inhibitors of erythropoiesis in patients with chronic renal failure. Tohoku J Exp Med. 1986;150:1-15. (Pubitemid 17212019)
34. Fehr T, Ammann P, Garzoni D, Korte W, Fierz W, Rickli H, Wuthrich RP. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004;66: 1206-1211. (Pubitemid 39121030)
35. Muller-Wiefel DE, Scharer K. Serum erythropoietin levels in children with chronic renal failure. Kidney Int. 1983;15(suppl):S70-S76.
36. Kato A, Hishida A, Kumagai H, Furuya R, Nakajima T, Honda N. Erythropoietin production in patients with chronic renal failure. Ren Fail. 1994;16:645-651. (Pubitemid 24371326)